Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etanercept + methylprednisolone
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Etanercept + methylprednisolone is a combination therapy investigated for the treatment of acute idiopathic pneumonia syndrome (IPS) following allogeneic hematopoietic cell transplantation (HCT). Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It functions as a TNF-alpha inhibitor by competitively binding to TNF-alpha and preventing its interaction with cell surface receptors. Methylprednisolone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties. The combination was evaluated in the Phase 3 BMT CTN 0403 trial, sponsored by the National Heart, Lung, and Blood Institute (NHLBI), but the study was terminated early due to poor patient accrual.
- Brand names
- Enbrel
- Other names
- etanercept + corticosteroidssoluble tumor necrosis factor receptor
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on etanercept + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etanercept + methylprednisolone.